{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:41:31Z","timestamp":1788302491618,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00417-022-05793-5","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:02:44Z","timestamp":1660122164000},"page":"345-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study"],"prefix":"10.1007","volume":"261","author":[{"given":"Tomoko","family":"Ueda-Consolvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Tanigichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Oiwake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2885-1141","authenticated-orcid":false,"given":"Atsushi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"5793_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","volume":"3","author":"PG Traine","year":"2019","unstructured":"Traine PG, Pfster IB, Zandi S et al (2019) Long term outcome of intravitreal afibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen. Ophthalmol Retina 3:393\u2013399. https:\/\/doi.org\/10.1016\/j.oret.2019.01.018","journal-title":"Ophthalmol Retina"},{"key":"5793_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2017.06.002","volume":"180","author":"FC DeCroos","year":"2017","unstructured":"DeCroos FC, Reed D, Adam MK et al (2017) Treat-and-extend therapy using afibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol 180:142\u2013150. https:\/\/doi.org\/10.1016\/j.ajo.2017.06.002","journal-title":"Am J Ophthalmol"},{"key":"5793_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA et al (2020) Efcacy and safety of intravitreal afibercept treat and-extend regimens in exudative age-related macular degeneration: 52- and 96-week fndings from ALTAIR: a randomized controlled trial. Adv Ther 37:1173\u20131187. https:\/\/doi.org\/10.1007\/s12325-020-01236-x","journal-title":"Adv Ther"},{"issue":"7","key":"5793_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Das A, Do DV et al (2020) Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology 127(7):963\u2013976. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.031","journal-title":"Ophthalmology"},{"key":"5793_CR5","doi-asserted-by":"publisher","first-page":"251584142110559","DOI":"10.1177\/25158414211055964","volume":"13","author":"RM Hussain","year":"2021","unstructured":"Hussain RM, Neal A, Yannuzzi NA et al (2021) Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments. Ther Adv Ophthalmol 13:25158414211055964. https:\/\/doi.org\/10.1177\/25158414211055964","journal-title":"Ther Adv Ophthalmol"},{"key":"5793_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05634-5","author":"A Boltz","year":"2022","unstructured":"Boltz A, Radunsky K, Weingessesl B et al (2022) Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to afibercept and bevacizumab. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-022-05634-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5793_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00908-1","author":"H Ota","year":"2022","unstructured":"Ota H, Takeuchi J, Nakano Y et al (2022) Switching from afibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-022-00908-1","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"5793_CR8","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/jcm10122666","volume":"10","author":"C Haensli","year":"2021","unstructured":"Haensli C, Pfister IB, Garweg JG (2021) Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6 month outcomes. J Clin Med 10(12):2666. https:\/\/doi.org\/10.3390\/jcm10122666","journal-title":"J Clin Med"},{"issue":"5","key":"5793_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 127(5):616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"issue":"9","key":"5793_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","volume":"30","author":"KB Freund","year":"2010","unstructured":"Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30(9):1333\u20131349. https:\/\/doi.org\/10.1097\/IAE.0b013e3181e7976b","journal-title":"Retina"},{"issue":"8","key":"5793_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453\u20131464. https:\/\/doi.org\/10.1097\/IAE.0b013e31824f91e8","journal-title":"Retina"},{"issue":"12","key":"5793_CR12","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1097\/IAE.0000000000002760","volume":"40","author":"A Fujita","year":"2020","unstructured":"Fujita A, Kataoka K, Takeuchi J et al (2020) Diagnostic characteristics of polypoidal choroidal vasculopathy based on B-scan swept-source optical coherence tomography angiography and its interrater agreement compared with indocyanine green angiography. Retina 40(12):2296\u20132303. https:\/\/doi.org\/10.1097\/IAE.0000000000002760","journal-title":"Retina"},{"key":"5793_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05517-1","author":"T Tamashiro","year":"2022","unstructured":"Tamashiro T, Tanaka K, Itagaki K et al (2022) Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-021-05517-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"5793_CR14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/biomedicines9091164","volume":"9","author":"Y Fukuda","year":"2021","unstructured":"Fukuda Y, Sakurada Y, Matsubara M et al (2021) Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines 9(9):1164. https:\/\/doi.org\/10.3390\/biomedicines9091164","journal-title":"Biomedicines"},{"key":"5793_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T et al (2012) Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119:1621\u20131627. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.022","journal-title":"Ophthalmology"},{"issue":"627\u2013633","key":"5793_CR16","doi-asserted-by":"publisher","first-page":"e621","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A et al (2015) Short-term changes in choroidal thickness after afibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159(627\u2013633):e621. https:\/\/doi.org\/10.1016\/j.ajo.2014.12.025","journal-title":"Am J Ophthalmol"},{"key":"5793_CR17","doi-asserted-by":"publisher","first-page":"44020","DOI":"10.1038\/srep44020","volume":"7","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Yoneyama S et al (2017) Incidence and risk factors of retreatment after three-monthly afibercept therapy for exudative age-related macular degeneration. Sci Rep 7:44020. https:\/\/doi.org\/10.1038\/srep44020","journal-title":"Sci Rep"},{"key":"5793_CR18","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","volume":"255","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Matsumoto H, Mimura K et al (2017) Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255:1891\u20131897. https:\/\/doi.org\/10.1007\/s00417-017-3718-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5793_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/OPTH.S30907","volume":"6","author":"AA Ellabban","year":"2012","unstructured":"Ellabban AA, Tsujikawa A, Ogino K et al (2012) Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 6:837\u2013844. https:\/\/doi.org\/10.2147\/OPTH.S30907","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"5793_CR20","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"issue":"7","key":"5793_CR21","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053","journal-title":"Ophthalmology"},{"issue":"14","key":"5793_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"issue":"14","key":"5793_CR23","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"issue":"4","key":"5793_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ajo.2015.06.030","volume":"160","author":"L Kuehlewein","year":"2015","unstructured":"Kuehlewein L, Bansal M, Lenis TL et al (2015) Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Am J Ophthalmol 160(4):739-748.e2. https:\/\/doi.org\/10.1016\/j.ajo.2015.06.030","journal-title":"Am J Ophthalmol"},{"key":"5793_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2017.12.005","volume":"187","author":"D Xu","year":"2018","unstructured":"Xu D, Davila JP, Rahimi M et al (2018) Long-term progression of type 1 neovascularization in age-related macular degeneration using optical coherence tomography angiography. Am J Ophthalmol 187:10\u201320. https:\/\/doi.org\/10.1016\/j.ajo.2017.12.005","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"5793_CR26","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Hoshino J, Mykai R et al (2021) Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep 11(1):6759. https:\/\/doi.org\/10.1038\/s41598-021-86014-7","journal-title":"Sci Rep"},{"issue":"18","key":"5793_CR27","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","volume":"31","author":"SJ Haug","year":"2020","unstructured":"Haug SJ, Hien DL, Uludag G et al (2020) Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep 31(18):100680. https:\/\/doi.org\/10.1016\/j.ajoc.2020.100680","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"10","key":"5793_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L et al (2020) Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology 127(10):1345\u20131359. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.017","journal-title":"Ophthalmology"},{"issue":"7","key":"5793_CR29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ et al (2021) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology 128(7):1050\u20131059. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011","journal-title":"Ophthalmology"},{"issue":"6","key":"5793_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","volume":"5","author":"CR Baumal","year":"2021","unstructured":"Baumal CR, Bodaghi B, Singer M et al (2021) Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina 5(6):519\u2013527. https:\/\/doi.org\/10.1016\/j.oret.2020.09.020","journal-title":"Ophthalmol Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05793-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:14:20Z","timestamp":1673525660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05793-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5793"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05793-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were in accordance with the ethical standards of the Institutional Review Board of the University of Toyama and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}